RAD-203

N/A

Report date: 2025/09/09 15:00:30

Base Information

Drug NameRAD-203

Drug Alias NameRAD-203

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Technetium > 99mTc +[4]

Mechanisms of ActionProgrammed death-ligand 1 modulators

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRadiopharm Theranostics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLantheus Medical Imaging Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A